Treatment effect of capecitabine and docetaxel or docetaxel alone byoestrogen receptor status in patients with metastatic breast cancer: Results of an exploratory analysis

Breast

Volumn 22, Issue 6, 2013, Pages 1087-1093

  Gluck S ^a   Russell, C ^b   O'Shaughnessy, J ^c   McKenna, E F ^d   Hu, S ^d   Odom, D ^e   Blum, J L ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c TEXAS ONCOLOGY   (United States)

^d GENENTECH INC   (United States)

^e RTI HEALTH SOLUTIONS   (United States)

Author keywords

Capecitabine; Docetaxel; Exploratory analysis; Hormone receptor status; Metastatic breast cancer; Survival

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; ESTROGEN RECEPTOR; PACLITAXEL;

ADULT; ARTICLE; ASTHENIA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE;

CAPECITABINE; DOCETAXEL; EXPLORATORY ANALYSIS; HORMONE RECEPTOR STATUS; METASTATIC BREAST CANCER; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TAXOIDS; TIME FACTORS;

EID: 84887135458     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.08.016     Document Type: Article

References (22)

1. Rosner D., Lane W.W., Nemoto T. Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study. Cancer 1998, 64:6-15.
2. Falkson G., Gelman R., Falkson C.L., Glick J., Harris J. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. JClin Oncol 1991, 9:2153-2161.
3. Rizzieri D.A., Vredenburgh J.J., Jones R., Ross M., Shpall E.J., Hussein A., et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. JClin Oncol 1999, 17:3064-3074.
4. Hohaus S., Funk L., Martin S., Schlenk R.F., Abdallah A., Hahn U., et al. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Br J Cancer 1999, 79:1500-1507.
5. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
6. Dunnwald L.K., Rossing M.A., Li C.I. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007, 9:R6.
7. O'Shaughnessy J., Miles D., Vukelja S., Moiseyenko V., Ayoub J.P., Cervantes G., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. JClin Oncol 2002, 20:2812-2823.
8. Brookmeyer R., Crowley J. Aconfidence interval for the median survival time. Biometrics 1982, 38:29-41.
9. Blum J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. JClin Oncol 1999, 17:485-493.
10. Blum J.L., Dieras V., Lo Russo P.M., Horton J., Rutman O., Buzdar A., et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92:1759-1768.
11. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. JClin Oncol 2005, 23:792-799.
12. Brufsky A.M., Hurvitz S., Perez E., Swamy R., Valero V., O'Neill V., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. JClin Oncol 2011, 29:4286-4293.
13. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. JClin Oncol 2011, 29:1252-1260.
14. ®) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001, 12:1247-1254.
15. Talbot D.C., Moiseyenko V., Van Belle S., O'Reilly S.M., Alba Conejo E., Ackland S., et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002, 86:1367-1372.
16. Blum J.L., Barrios C.H., Feldman N., Verma S., McKenna E.F., Lee L.F., et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2012, 136:777-788.
17. Gilabert M., Bertucci F., Esterni B., Madroszyk A., Tarpin C., Jacquemier J., et al. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res 2011, 31:1079-1086.
18. von Minckwitz G., Rezai M., Loibl S., Fasching P.A., Huober J., Tesch H., et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. JClin Oncol 2010, 28:2015-2023.
19. Steger G.G., Greil R., Jakesz R., Lang A., Mlineritsch B., Rudas M., et al. Pathologic complete response in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer. JClin Oncol 2010, 28(Suppl.15). [abstr 530].
20. Joensuu H., Kellokumpu-Lehtinen P.L., Huovinen R., Jukkola-Vuorinen A., Tanner M., Kokko R., et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. JClin Oncol 2012, 30:11-18.
21. O'Shaughnessy J., Paul D., Stokoe C., Pippen J., Blum J.L., Krekow L., et al. First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. Cancer Res 2010, 70(Suppl.24). [abstr S4-2 and presentation].
22. Glück S., Ross J.S., Royce M., McKenna E.F., Perou C.M., Avisar E., et al. TP53 genomics predicts higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine±trastuzumab. Breast Cancer Res Treat 2012, 132:781-791.